GC Green Cross Selects Priority Negotiation Candidate for COVID-19 Plasma Therapy

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross announced on the 4th that it has been finally selected as the priority negotiation candidate for the research service project by the Korea Disease Control and Prevention Agency for the development of a novel coronavirus disease (COVID-19) plasma treatment.

GC Green Cross is simultaneously conducting clinical trials to confirm the therapeutic efficacy of the COVID-19 plasma treatment 'GC5131A' and preparing for commercial production. The clinical trials are scheduled to begin by July at the latest.

A GC Green Cross official stated, "We are developing the plasma treatment with two objectives: urgent treatment of COVID-19 patients and securing a platform for treatments of emerging infectious diseases that may occur in the future," adding, "Test production for mass production of the treatment has already been successfully completed at the Ochang plant."

This content was produced with the assistance of AI translation services.